1482 related articles for article (PubMed ID: 28224296)
1. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
Wong CKH; Lang BHH; Yu HMS; Lam CLK
Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
[TBL] [Abstract][Full Text] [Related]
2. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
Cheung PWH; Wong CKH; Cheung JPY
Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
[TBL] [Abstract][Full Text] [Related]
3. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
[TBL] [Abstract][Full Text] [Related]
4. Comparison of EQ-5D-5L, VAS, and SF-6D in Thai Patients on Peritoneal Dialysis.
Thaweethamcharoen T; Noparatayaporn P; Sritippayawan S; Aiyasanon N
Value Health Reg Issues; 2019 May; 18():59-64. PubMed ID: 30502661
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
[TBL] [Abstract][Full Text] [Related]
6. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
Selva-Sevilla C; Ferrara P; Gerónimo-Pardo M
Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
[TBL] [Abstract][Full Text] [Related]
7. Comparative performance of the EQ-5D-5L and SF-6D index scores in adults with type 2 diabetes.
Sayah FA; Qiu W; Xie F; Johnson JA
Qual Life Res; 2017 Aug; 26(8):2057-2066. PubMed ID: 28364183
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.
Xu RH; Dong D; Luo N; Wong EL; Wu Y; Yu S; Yang R; Liu J; Yuan H; Zhang S
Eur J Health Econ; 2021 Jun; 22(4):547-557. PubMed ID: 33761029
[TBL] [Abstract][Full Text] [Related]
9. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D.
Shiroiwa T; Fukuda T; Ikeda S; Igarashi A; Noto S; Saito S; Shimozuma K
Qual Life Res; 2016 Mar; 25(3):707-19. PubMed ID: 26303761
[TBL] [Abstract][Full Text] [Related]
10. Psychometric properties of the five-level EuroQoL-5 dimension and Short Form-6 dimension measures of health-related quality of life in a population of pregnant women with depression.
Heslin M; Chua KC; Trevillion K; Nath S; Howard LM; Byford S
BJPsych Open; 2019 Oct; 5(6):e88. PubMed ID: 31588885
[TBL] [Abstract][Full Text] [Related]
11. Validity and responsiveness of EQ-5D-5L and SF-6D in patients with health complaints attributed to their amalgam fillings: a prospective cohort study of patients undergoing amalgam removal.
Lamu AN; Björkman L; Hamre HJ; Alræk T; Musial F; Robberstad B
Health Qual Life Outcomes; 2021 Apr; 19(1):125. PubMed ID: 33865400
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing health-related quality-of-life and utility measures between routine fine-needle aspiration cytology (FNAC) and surveillance alone in patients with thyroid incidentaloma measuring 1-2 cm.
Wong CKH; Lang BHH
Endocrine; 2020 Feb; 67(2):397-405. PubMed ID: 31741168
[TBL] [Abstract][Full Text] [Related]
13. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population.
Petrou S; Hockley C
Health Econ; 2005 Nov; 14(11):1169-89. PubMed ID: 15942981
[TBL] [Abstract][Full Text] [Related]
14. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
15. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
16. A Head-to-Head Comparison of UK SF-6D and Thai and UK EQ-5D-5L Value Sets in Thai Patients with Chronic Diseases.
Sakthong P; Munpan W
Appl Health Econ Health Policy; 2017 Oct; 15(5):669-679. PubMed ID: 28290106
[TBL] [Abstract][Full Text] [Related]
17. A review of the psychometric properties of generic utility measures in multiple sclerosis.
Kuspinar A; Mayo NE
Pharmacoeconomics; 2014 Aug; 32(8):759-73. PubMed ID: 24846760
[TBL] [Abstract][Full Text] [Related]
18. Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia.
Abdin E; Chong SA; Seow E; Verma S; Tan KB; Subramaniam M
Qual Life Res; 2019 Jan; 28(1):177-186. PubMed ID: 30382480
[TBL] [Abstract][Full Text] [Related]
19. A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population.
Kangwanrattanakul K
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):765-774. PubMed ID: 32981380
[TBL] [Abstract][Full Text] [Related]
20. Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients.
Zhao FL; Yue M; Yang H; Wang T; Wu JH; Li SC
Value Health; 2010 Aug; 13(5):649-56. PubMed ID: 20412540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
